Uveitis Pipeline Insights and Analysis 2024: FDA Approvals and Clinical Trials Developments by DelveInsight | AbbVie, Novartis, Allergan, Bausch & Lomb, Santen Pharma, Eyegate Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Uveitis pipeline constitutes 15+ key companies continuously working towards developing 15+ Uveitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Uveitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uveitis Market.

The Uveitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Uveitis Pipeline Report: https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Uveitis treatment therapies with a considerable amount of success over the years.
• Uveitis companies working in the treatment market are Priovant Therapeutics, Inc., ACELYRIN Inc., Bio-Thera Solutions, Eli Lilly and Company, Massachusetts Eye Research, Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others, are developing therapies for the Uveitis treatment
• Emerging Uveitis therapies in the different phases of clinical trials are- Brepocitinib PO QD, Izokibep, QLETLI, Baricitinib, Ixekizumab Prefilled Syringe, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others are expected to have a significant impact on the Uveitis market in the coming years.
• In September 2024, Priovant Therapeutics has announced the enrollment of the first patients in CLARITY, a Phase 3 study investigating brepocitinib for non-anterior non-infectious uveitis (NIU). Additionally, brepocitinib has received Fast Track Designation from the FDA for NIU. The Fast Track process is aimed at accelerating the development and review of drugs that address serious conditions and unmet medical needs.
• In April 2024, Roivant and Priovant Therapeutics announced positive results from the Phase II NEPTUNE clinical trial of brepocitinib for non-anterior non-infectious uveitis (NIU). The double-blind trial included 26 participants with active NIU, who were randomized in a 2:1 ratio to receive either 45mg or 15mg of brepocitinib daily. The study also included an initial prednisone burst of 60mg per day for two weeks, followed by a six-week tapering period.
• In January 2024, Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company specializing in first-in-class therapies for blinding ocular diseases, announced that it has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA). This agreement pertains to the clinical trial protocol and planned statistical analysis for the Tarsier-04 Phase 3 trial, which will evaluate TRS01 eye drops for treating non-infectious uveitis, including uveitic glaucoma.

Uveitis Overview
Uveitis is an inflammation of the uvea, the middle layer of the eye that includes the iris, ciliary body, and choroid. It can be caused by infections, autoimmune disorders, or injuries, and can lead to symptoms like eye redness, pain, blurred vision, light sensitivity, and floaters. If left untreated, uveitis can result in serious complications, such as glaucoma, cataracts, or even vision loss. Treatment typically involves anti-inflammatory medications like corticosteroids, and in some cases, immunosuppressive drugs or biologics may be used depending on the underlying cause. Regular eye exams are important for early detection and management.

Get a Free Sample PDF Report to know more about Uveitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Uveitis Drugs Under Different Phases of Clinical Development Include:
• Brepocitinib PO QD: Priovant Therapeutics, Inc.
• Izokibep: ACELYRIN Inc.
• QLETLI: Bio-Thera Solutions
• Baricitinib: Eli Lilly and Company
• Ixekizumab Prefilled Syringe: Massachusetts Eye Research
• ESK-001: Alumis Inc
• OCS-01: Quan Dong Nguyen
• Dusquetide: Soligenix
• Hemay005: Ganzhou Hemay Pharmaceutical
• Apremilast: Amgen

Uveitis Route of Administration
Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Uveitis Molecule Type
Uveitis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Uveitis Pipeline Therapeutics Assessment
• Uveitis Assessment by Product Type
• Uveitis By Stage and Product Type
• Uveitis Assessment by Route of Administration
• Uveitis By Stage and Route of Administration
• Uveitis Assessment by Molecule Type
• Uveitis by Stage and Molecule Type

DelveInsight's Uveitis Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Uveitis product details are provided in the report. Download the Uveitis pipeline report to learn more about the emerging Uveitis therapies
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Uveitis Therapeutics Market include:
Key companies developing therapies for Uveitis are - AbbVie Inc., Novartis AG, Allergan Inc., Bausch & Lomb Incorporated, Santen Pharmaceutical Co. Ltd, Eyegate Pharmaceuticals Inc., Regeneron Pharmaceuticals, Eyepoint Pharmaceuticals Inc., Alimera Sciences Inc., and others.

Uveitis Pipeline Analysis:
The Uveitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Uveitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uveitis Treatment.
• Uveitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uveitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uveitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Uveitis drugs and therapies
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Uveitis Pipeline Market Strengths
• The remarkable advances in ocular immunology over the past decades have led to a better understanding of the molecular mechanisms that underlie etiology and susceptibility to uveitis
• New drugs with diverse mechanisms of action and routes of administration have been approved in the recent past, improving the treatment regime

Uveitis Pipeline Market Opportunities
• Opportunity for companies to implement knowledge from recent advances in understanding the etiologies associated with uveitis to evaluate potential drugs with novel targets
• Biomarker discovery and proteomics provide potential targets for therapeutic intervention by the drugs that are available and accessible, besides providing information about the drug that can be avoided

Scope of Uveitis Pipeline Drug Insight
• Coverage: Global
• Key Uveitis Companies: Priovant Therapeutics, Inc., ACELYRIN Inc., Bio-Thera Solutions, Eli Lilly and Company, Massachusetts Eye Research, Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others
• Key Uveitis Therapies: Brepocitinib PO QD, Izokibep, QLETLI, Baricitinib, Ixekizumab Prefilled Syringe, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others
• Uveitis Therapeutic Assessment: Uveitis current marketed and Uveitis emerging therapies
• Uveitis Market Dynamics: Uveitis market drivers and Uveitis market barriers

Request for Sample PDF Report for Uveitis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Uveitis Report Introduction
2. Uveitis Executive Summary
3. Uveitis Overview
4. Uveitis- Analytical Perspective In-depth Commercial Assessment
5. Uveitis Pipeline Therapeutics
6. Uveitis Late Stage Products (Phase II/III)
7. Uveitis Mid Stage Products (Phase II)
8. Uveitis Early Stage Products (Phase I)
9. Uveitis Preclinical Stage Products
10. Uveitis Therapeutics Assessment
11. Uveitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Uveitis Key Companies
14. Uveitis Key Products
15. Uveitis Unmet Needs
16 . Uveitis Market Drivers and Barriers
17. Uveitis Future Perspectives and Conclusion
18. Uveitis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Uveitis Epidemiology https://www.delveinsight.com/report-store/uveitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Uveitis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.